Want to see CRIS full AI Analyst Report?
Top Page
Curis
(NASDAQ:CRIS)
Select Model
Select Model
Rating:46Neutral
Price Target:
$0.34
▼(-43.50% Downside)
Action:Reiterated
Date:07/01/26
Overall score is held down primarily by weak financial performance (large ongoing losses and significant cash burn) and added listing/financing overhangs. Partially offsetting this are positive clinical and regulatory milestones from the latest earnings call and modest near-term technical stabilization, though the longer-term price trend remains negative.
Positive Factors
Registrational PCNSL Program
A clearly defined registrational TakeAim Lymphoma study with an ORR endpoint and on‑track enrollment creates a durable regulatory pathway. Successful execution could enable accelerated U.S./EU submissions, materially de‑risking one lead program and improving long‑term commercialization prospects and partner interest.
Negative Factors
Persistent Cash Burn
Sustained negative operating and free cash flow forces repeated external financing or milestone‑dependent funding. This structural cash burn increases dilution risk and can interrupt development timelines if financing stalls, making long‑term program continuity contingent on successful near‑term capital events or partnerships.
Read all positive and negative factors
Positive Factors
Negative Factors
Registrational PCNSL Program
A clearly defined registrational TakeAim Lymphoma study with an ORR endpoint and on‑track enrollment creates a durable regulatory pathway. Successful execution could enable accelerated U.S./EU submissions, materially de‑risking one lead program and improving long‑term commercialization prospects and partner interest.
Read all positive factors
Curis (CRIS) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$13.51M
Dividend YieldN/A
Average Volume (3M)68.01K
Price to Earnings (P/E)―
Beta (1Y)3.16
Revenue Growth-36.95%
EPS Growth80.84%
CountryUS
Employees24
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.19
Shares Outstanding38,978,690
10 Day Avg. Volume74,344
30 Day Avg. Volume68,010
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)23.79
Price to Sales (P/S)13.76
P/FCF Ratio-4.78
Enterprise Value/Market Cap-0.62
Enterprise Value/Revenue-1.18
Enterprise Value/Gross Profit-1.18
Enterprise Value/Ebitda0.41
Forecast
1Y Price Target
$11.00Price Target Upside1733.33% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-1.58
Revenue Forecast (FY)$1.75M
Curis Business Overview & Revenue Model
Company Description
Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small-molecule IRAK4 kinase ...
How the Company Makes Money
Curis primarily generates revenue through collaboration arrangements and related payments from partners, rather than from product sales. These collaboration revenues can include upfront payments, research funding or cost reimbursements, milestone ...
Curis Earnings Call Summary
Earnings Call Date:May 12, 2026
(Q1-2026)
| % Change Since: |
Next Earnings Date:Jul 30, 2026
Earnings Call Sentiment Positive
The call conveyed meaningful clinical progress and clear near‑term milestones — notably advancement of a registrational PCNSL study with the potential for accelerated submissions, initiation and early milestones for a CLL proof‑of‑concept study, encouraging early collaborator data in gastroesophageal cancer, and collaborative/regulatory engagement. Offsetting these positives are a sizable increase in reported net loss (driven by warrant fair‑value changes), higher G&A tied to financing, a cash runway that depends in part on a milestone contingent warrant exercise, and expected enrollment variability in ultra‑orphan indications. On balance, the clinical and regulatory momentum and near‑term data/milestone visibility materially outweigh the financial and enrollment risks described.Positive Updates
Progress on TakeAim Lymphoma (PCNSL) Registrational Study
Continued steady progress on the single-arm registrational TakeAim Lymphoma study in relapsed/refractory primary CNS lymphoma (PCNSL) with an ORR endpoint; company expects the study to support accelerated submissions in the U.S. and Europe and anticipates updated combination data with ibrutinib in the first half of 2027. Enrollment is described as 'on track' despite the ultra-orphan patient population.
Negative Updates
Significant Increase in Net Loss
Net loss widened to $24.2 million ($1.25 per share) in Q1 2026 from $10.6 million ($1.25 per share) in Q1 2025 — a dollar increase of $13.6 million representing a ~128.3% increase year‑over‑year; increase driven primarily by change in fair value of warrant liabilities related to the January 2026 PIPE financing.
Read all updates
Q1-2026 Updates
Positive
Negative
Progress on TakeAim Lymphoma (PCNSL) Registrational Study
Continued steady progress on the single-arm registrational TakeAim Lymphoma study in relapsed/refractory primary CNS lymphoma (PCNSL) with an ORR endpoint; company expects the study to support accelerated submissions in the U.S. and Europe and anticipates updated combination data with ibrutinib in the first half of 2027. Enrollment is described as 'on track' despite the ultra-orphan patient population.
Read all positive updates
Company Guidance
The company provided specific operational and financial guidance: clinically, Curis expects to dose the initial five patients in the TakeAim CLL zanubrutinib combination study by mid‑2026 with initial data expected in December 2026, will evaluate 100 mg and 200 mg emavusertib (having dosed up to 500 mg historically) to satisfy Project Optimus, and plans to provide updated emavusertib/ibrutinib TakeAim Lymphoma (r/r PCNSL) data — and a substantial enrollment update toward potential full enrollment — in the first half of 2027; separately, a gastric/esophageal cohort presented 16 evaluable patients showing a manageable toxicity profile and encouraging preliminary results. Financially, Q1 2026 net loss was $24.2 million ($1.25 per share) versus a $10.6 million loss ($1.25 per share) in Q1 2025 (R&D $6.4M vs $8.5M year‑over‑year; G&A $5.1M vs $4.0M), and Curis had $15.0 million cash and cash equivalents as of March 31, 2026 plus anticipated gross proceeds of up to $20.2 million from exercise of January 2026 Series B PIPE warrants contingent on public announcement of dosing the fifth CLL patient — amounts the company says should fund planned operations into the second half of 2027.Curis Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
56
Neutral
Cash Flow
14
Very Negative
| Breakdown | TTM | Dec 2025 | Mar 2025 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 7.06M | 9.44M | 10.91M | 10.02M | 10.16M | 10.65M |
| Gross Profit | 7.02M | 9.40M | 10.81M | 9.81M | 9.90M | 10.12M |
| EBITDA | -20.46M | -5.23M | -42.57M | -45.14M | -51.67M | -40.81M |
| Net Income | -21.16M | -7.58M | -43.39M | -47.41M | -56.67M | -45.44M |
Balance Sheet | ||||||
| Total Assets | 29.69M | 19.97M | 41.27M | 77.28M | 108.85M | 162.30M |
| Cash, Cash Equivalents and Short-Term Investments | 15.00M | 5.06M | 20.00M | 56.33M | 85.62M | 115.88M |
| Total Debt | 1.34M | 1.62M | 2.95M | 2.79M | 3.94M | 5.04M |
| Total Liabilities | 16.98M | 14.50M | 47.26M | 57.61M | 62.30M | 71.59M |
| Stockholders Equity | 12.71M | 5.46M | -6.00M | 19.67M | 46.55M | 90.71M |
Cash Flow | ||||||
| Free Cash Flow | -28.95M | -27.20M | -39.56M | -38.43M | -54.75M | -37.62M |
| Operating Cash Flow | -28.95M | -27.20M | -39.56M | -38.43M | -54.34M | -37.62M |
| Investing Cash Flow | 2.50M | 2.50M | 29.44M | 37.79M | 33.02M | -47.90M |
| Financing Cash Flow | 21.17M | 9.77M | 3.44M | 7.58M | 867.00K | -4.17M |
Curis Technical Analysis
Negative
0.60
Price Trends
0.49
Negative
0.66
Negative
0.97
Negative
Market Momentum
-0.03
Negative
43.84
Neutral
64.27
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CRIS, the sentiment is Negative. The current price of 0.6 is above the 20-day moving average (MA) of 0.41, above the 50-day MA of 0.49, and below the 200-day MA of 0.97, indicating a bearish trend. The MACD of -0.03 indicates Negative momentum. The RSI at 43.84 is Neutral, neither overbought nor oversold. The STOCH value of 64.27 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CRIS.
Curis Risk Analysis
Curis disclosed 59 risk factors in its most recent earnings report. Curis reported the most risks in the "Legal & Regulatory" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Curis Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
56 Neutral | $83.82M | -10.61 | -14.39% | ― | 1.18% | 83.26% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $14.09M | -0.09 | ― | ― | ― | 80.65% | |
47 Neutral | $6.28M | -1.40 | -79.47% | ― | -100.00% | 62.88% | |
46 Neutral | $13.51M | -0.29 | 354.21% | ― | -36.95% | 80.84% | |
46 Neutral | $5.85M | -0.24 | -226.28% | 10.27% | 10792.86% | 99.40% |
* Healthcare Sector Average
CRIS
Curis
0.35
-1.39
-80.11%
BGMS
Bio Green Med Solution
1.06
-2.51
-70.31%
MBRX
Moleculin Biotech
2.64
-7.08
-72.84%
PULM
Pulmatrix
1.72
-4.94
-74.17%
RLYB
Rallybio
15.82
13.09
480.79%
Curis Corporate Events
Business Operations and StrategyStock Split
Curis Implements 1-for-20 Reverse Stock Split
Neutral
Jul 2, 2026
On July 2, 2026, Curis, Inc. implemented a 1-for-20 reverse stock split of its issued and outstanding common shares, converting every 20 existing shares into one new share, with fractional shares rounded up to the nearest whole share. The reverse ...
Shareholder MeetingsStock Split
Curis Stockholders Approve 1-for-20 Reverse Split
Neutral
Jul 1, 2026
Curis, Inc. held a special meeting of stockholders on June 25, 2026, where shareholders approved amendments to the company’s Restated Certificate of Incorporation to authorize a reverse stock split in a range between 1-for-5 and 1-for-25, su...
Delistings and Listing ChangesShareholder MeetingsStock Split
Curis Shareholders Approve Flexible Reverse Stock Split Authorization
Positive
Jun 25, 2026
On June 25, 2026, Curis, Inc. held a special meeting of stockholders at which investors approved amendments to its Restated Certificate of Incorporation to authorize a reverse stock split of its common stock at a ratio between 1-for-5 and 1-for-25...
Business Operations and StrategyExecutive/Board ChangesShareholder Meetings
Curis Shareholders Approve Expanded Capital Structure and Governance
Positive
May 22, 2026
On May 19, 2026, Curis stockholders approved an amendment to the company’s Restated Certificate of Incorporation, increasing authorized capital stock to 572,514,300 shares and authorized common stock to 567,514,300 shares, with the new commo...
Delistings and Listing ChangesRegulatory Filings and Compliance
Curis Faces Nasdaq Delisting Determination, Plans Appeal Hearing
Negative
May 1, 2026
On February 3, 2026, Curis, Inc. became subject to a one-year Discretionary Panel Monitor under Nasdaq Listing Rule 5815(d)(4)(A), meaning that any renewed noncompliance with Nasdaq rules during this period could trigger an accelerated delisting p...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.